Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Recent Patents on Nanotechnology
  4. Volume 19, Issue 1
  5. Article
Volume 19, Issue 1
  • ISSN: 1872-2105
  • E-ISSN: 2212-4020

Abstract

The convergence of diabetology and nanotechnology has emerged as a promising synergy with the potential to revolutionize the management and treatment of diabetes mellitus. Diabetes, a complex metabolic disorder affecting millions worldwide, necessitates innovative approaches to enhance monitoring, diagnosis, and therapeutic interventions. Nanotechnology, a burgeoning field that manipulates materials at the nanoscale, offers unprecedented opportunities to address the challenges posed by diabetes. This abstract explores the multifaceted interface between diabetology and nanotechnology, highlighting key areas of integration. Nanotechnology has paved the way for the development of advanced glucose monitoring systems with enhanced accuracy, sensitivity, and patient convenience. Miniaturized biosensors and implantable devices equipped with nanoscale materials enable continuous and real-time glucose monitoring, empowering individuals with diabetes to make timely and informed decisions about their dietary and insulin management. Furthermore, nanotechnology has facilitated breakthroughs in targeted drug delivery, addressing the limitations of conventional therapies in diabetes treatment. Nano-sized drug carriers can improve bioavailability, enable controlled release, and enhance the selectivity of therapeutic agents, minimizing side effects and optimizing treatment outcomes. Moreover, nanoengineered materials have opened avenues for tissue engineering and regenerative medicine, offering the potential to restore damaged pancreatic islets and insulin-producing cells. The amalgamation of diabetology and nanotechnology also holds promise for early disease detection and prevention. Nanoscale diagnostic tools, such as biomarker-based nanoprobes and lab-on-chip devices, offer rapid and accurate detection of diabetes-related biomolecules, enabling timely interventions and reducing the risk of complications. However, this compelling combination also presents challenges that warrant careful consideration. Safety, biocompatibility, regulatory approval, and ethical implications are crucial factors that demand meticulous evaluation during the translation of nanotechnology-based solutions into clinical practice. In conclusion, the integration of diabetology and nanotechnology represents a transformative paradigm that has the potential to reshape the landscape of diabetes management. By harnessing the unique properties of nanoscale materials, researchers and clinicians are poised to usher in an era of personalized and precise diagnostics, therapeutics, and preventive strategies for diabetes mellitus. As advancements in nanotechnology continue to unfold, the journey towards realizing the full potential of this compelling combination remains an exciting frontier in medical science. This review has thoroughly and critically studied the usage of nanomedicine in the diagnosis, monitoring, and management of diabetes and its effects, providing a clear picture of their potential clinical application in the future. This evaluation covers additional numerous clinical trials research and patents that are currently in way in this subject. Thus in the light of this we intended to provide a broad picture of the state of technological development in the area of diabetes management through nanotechnology.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/nanotec/10.2174/0118722105253055231016155618
2023-11-02
2024-12-26

  • From This Site

    /content/journals/nanotec/10.2174/0118722105253055231016155618
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. HeY. Al-MureishA. WuN. Nanotechnology in the treatment of diabetic complications: A comprehensive narrative review.J. Diabetes Res.2021202111110.1155/2021/661206334007847
     [Google Scholar]
  2. SharmaR. BorahS.J. KumarS. Emerging trends in nano-based antidiabetic therapeutics: A path to effective diabetes management.Mater. Adv.20234153091311310.1039/D3MA00159H
     [Google Scholar]
  3. LiuM. WeiX. ZhengZ. Recent advances in nano-drug delivery systems for the treatment of diabetic wound healing.Int. J. Nanomedicine2023181537156010.2147/IJN.S39543837007988
     [Google Scholar]
  4. PatraP. ChoudhuryS. Recent developments in nano-formulations against diabetes.Recent Pat. Nanotechnol.202317434035810.2174/187221051666622062211450535733310
     [Google Scholar]
  5. TurnerR. HolmanR. MatthewsD. UK prospective diabetes study (UKPDS).Diabetologia1991341287789010.1007/BF004001951778353
     [Google Scholar]
  6. ZhangY. PanX.F. ChenJ. Combined lifestyle factors and risk of incident type 2 diabetes and prognosis among individuals with type 2 diabetes: A systematic review and meta-analysis of prospective cohort studies.Diabetologia2020631213310.1007/s00125‑019‑04985‑931482198
     [Google Scholar]
  7. EnglerP.A. RamseyS.E. SmithR.J. Alcohol use of diabetes patients: The need for assessment and intervention.Acta Diabetol.2013502939910.1007/s00592‑010‑0200‑x20532803
     [Google Scholar]
  8. RossiG. Diagnosis and classification of diabetes mellitus.Recenti Prog. Med.20101017-827427620842952
     [Google Scholar]
  9. US Food and Drug Administration.FDA approves novel, dual-targeted treatment for type 2 diabetes.FDA News Release2022
     [Google Scholar]
  10. BertschT. An Introduction to tirzepatide.Clin. Diabetes202240337137210.2337/cd22‑003835983423
     [Google Scholar]
  11. PiemontiL. KeymeulenB. GillardP. Ladarixin, an inhibitor of the interleukin-8 receptors CXCR1 and CXCR2, in new-onset type 1 diabetes: A multicentre, randomized, double-blind, placebo-controlled trial.Diabetes Obes. Metab.20222491840184910.1111/dom.1477035589610
     [Google Scholar]
  12. KawaiT. SunB. YoshinoH. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist.Proc. Natl. Acad. Sci.202011747299592996710.1073/pnas.201487911733177239
     [Google Scholar]
  13. DiSantoR.M. SubramanianV. GuZ. Recent advances in nanotechnology for diabetes treatment.Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.20157454856410.1002/wnan.132925641955
     [Google Scholar]
  14. VeisehO. TangB.C. WhiteheadK.A. AndersonD.G. LangerR. Managing diabetes with nanomedicine: Challenges and opportunities.Nat. Rev. Drug Discov.2015141455710.1038/nrd447725430866
     [Google Scholar]
  15. DevadasuV.R. AlshammariT.M. AljofanM. Current advances in the utilization of nanotechnology for the diagnosis and treatment of diabetes.Int. J. Diabetes Dev. Ctries.2018381111910.1007/s13410‑017‑0558‑1
     [Google Scholar]
  16. LiuY. ZengS. JiW. Emerging theranostic nanomaterials in diabetes and its complications.Adv. Sci.202293210246610.1002/advs.202102466
     [Google Scholar]
  17. LiebermanS.M. DiLorenzoT.P. A comprehensive guide to antibody and T-cell responses in type 1 diabetes.Tissue Antigens200362535937710.1034/j.1399‑0039.2003.00152.x14617043
     [Google Scholar]
  18. ReinerT. ThurberG. GagliaJ. Accurate measurement of pancreatic islet β-cell mass using a second-generation fluorescent exendin-4 analog.Proc. Natl. Acad. Sci.201110831128151282010.1073/pnas.110985910821768367
     [Google Scholar]
  19. CashK.J. ClarkH.A. Nanosensors and nanomaterials for monitoring glucose in diabetes.Trends Mol. Med.2010161258459310.1016/j.molmed.2010.08.00220869318
     [Google Scholar]
  20. VaddirajuS. BurgessD.J. TomazosI. JainF.C. PapadimitrakopoulosF. Technologies for continuous glucose monitoring: Current problems and future promises.J. Diabetes Sci. Technol.2010461540156210.1177/19322968100040063221129353
     [Google Scholar]
  21. LamprianouS. ImmonenR. NabuursC. High-resolution magnetic resonance imaging quantitatively detects individual pancreatic islets.Diabetes201160112853286010.2337/db11‑072621926272
     [Google Scholar]
  22. EdelmanS.V. ArgentoN.B. PettusJ. HirschI.B. Clinical implications of real-time and intermittently scanned continuous glucose monitoring.Diabetes Care201841112265227410.2337/dc18‑115030348844
     [Google Scholar]
  23. AnsariS.G. AnsariZ.A. WahabR. KimY.S. KhangG. ShinH.S. Glucose sensor based on nano-baskets of tin oxide templated in porous alumina by plasma enhanced CVD.Biosens. Bioelectron.200823121838184210.1016/j.bios.2008.02.02218395436
     [Google Scholar]
  24. BankarS.B. BuleM.V. SinghalR.S. AnanthanarayanL. Glucose oxidase: An overview.Biotechnol. Adv.200927448950110.1016/j.biotechadv.2009.04.00319374943
     [Google Scholar]
  25. SubramaniK. PathakS. HosseinkhaniH. Recent trends in diabetes treatment using nanotechnology.Dig. J. Nanomater. Biostruct.2012718595
     [Google Scholar]
  26. SurendiranA. SandhiyaS. PradhanS.C. AdithanC. Novel applications of nanotechnology in medicine.Indian J. Med. Res.2009130668970120090129
     [Google Scholar]
  27. ChoudhuryH. GorainB. KarmakarS. Improvement of cellular uptake, in vitro antitumor activity and sustained release profile with increased bioavailability from a nanoemulsion platform.Int. J. Pharm.20144601-213114310.1016/j.ijpharm.2013.10.05524239580
     [Google Scholar]
  28. GorainB. ChoudhuryH. TekadeR.K. KaranS. JaisankarP. PalT.K. Comparative biodistribution and safety profiling of olmesartan medoxomil oil-in-water oral nanoemulsion.Regul. Toxicol. Pharmacol.201682203110.1016/j.yrtph.2016.10.02027815174
     [Google Scholar]
  29. ChallS. MatiS.S. GorainB. RakshitS. BhattacharyaS.C. Toxicological assessment of PEG functionalized f-block rare earth phosphate nanorods.Toxicol. Res.20154496697510.1039/C5TX00049A
     [Google Scholar]
  30. GorainB. ChoudhuryH. KunduA. Nanoemulsion strategy for olmesartan medoxomil improves oral absorption and extended antihypertensive activity in hypertensive rats.Colloids Surf. B Biointerfaces201411528629410.1016/j.colsurfb.2013.12.01624388859
     [Google Scholar]
  31. LagopatiN. PavlatouE. Nanotechnology in diabetes management.Integr. Obes. Diabetes20215419424
     [Google Scholar]
  32. LemmermanL.R. DasD. Higuita-CastroN. MirmiraR.G. Gallego-PerezD. Nanomedicine-based strategies for diabetes: Diagnostics, monitoring, and treatment.Trends Endocrinol. Metab.202031644845810.1016/j.tem.2020.02.00132396845
     [Google Scholar]
  33. BoisseauP. LoubatonB. Nanomedicine, nanotechnology in medicine.C. R. Phys.201112762063610.1016/j.crhy.2011.06.001
     [Google Scholar]
  34. PetersD. KastantinM. KotamrajuV.R. Targeting atherosclerosis by using modular, multifunctional micelles.Proc. Natl. Acad. Sci.2009106249815981910.1073/pnas.090336910619487682
     [Google Scholar]
  35. TangJ. SuT. HuangK. Targeted repair of heart injury by stem cells fused with platelet nanovesicles.Nat. Biomed. Eng.201821172610.1038/s41551‑017‑0182‑x29862136
     [Google Scholar]
  36. ChangD. LimM. GoosJ.A.C.M. Biologically targeted magnetic hyperthermia: Potential and limitations.Front. Pharmacol.2018983110.3389/fphar.2018.0083130116191
     [Google Scholar]
  37. WangL. HuC. ShaoL. The antimicrobial activity of nanoparticles: Present situation and prospects for the future.Int. J. Nanomedicine2017121227124910.2147/IJN.S12195628243086
     [Google Scholar]
  38. KumariS. KambojV.K. RajpootD. TeotiaA.K. VermaP.K. SinghG.N. The Unprecedented role of gold nanomaterial in diabetes management.Recent Pat. Drug Deliv. Formul.202013321922710.2174/187152651866618111416535230430950
     [Google Scholar]
  39. ArasO. FleiterT. JeudyJ. DanielM.C. U.S. Patent Application No. 12/927,323.
     [Google Scholar]
  40. WangooN. SwamiA. KaurS. BansalK. SharmaR.K. Development of a colloidal gold-based nanobioprobe for the detection of glycated albumin.Bionanoscience20166213213810.1007/s12668‑016‑0203‑3
     [Google Scholar]
  41. BrandauW. FischlerM. Jahnen-dechentW. Search for application.US Patent Application No. 12/0603992008
     [Google Scholar]
  42. KawdeA.N.M.A. AzizM.A. Search for application.US Patent Application No. 14/0424192015
     [Google Scholar]
  43. ZhangW. DuY. WangM.L. On-chip highly sensitive saliva glucose sensing using multilayer films composed of single-walled carbon nanotubes, gold nanoparticles, and glucose oxidase.Sens. Biosensing Res.201549610210.1016/j.sbsr.2015.04.006
     [Google Scholar]
  44. ZhangW. WangM.L. Washington, DC: U.S. Patent and trademark office. US Patent No. 9244035,2016
     [Google Scholar]
/content/journals/nanotec/10.2174/0118722105253055231016155618
Loading
Diabetology and Nanotechnology: A Compelling Combination
Recent Pat Nanotechnol 19, 4 (2025); https://doi.org/10.2174/0118722105253055231016155618
/content/journals/nanotec/10.2174/0118722105253055231016155618
/content/journals/nanotec/10.2174/0118722105253055231016155618
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): anti-diabetic drug delivery; diabetes mellitus; diagnosis; nanoparticles; nanoscale diagnostic tools; Nanotechnology

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test